title: Gabapentin for smoking cessation.
abstract: BACKGROUND
  We conducted a preliminary proof-of-concept study evaluating gabapentin for the treatment of tobacco dependence.
  
  
  METHODS
  Subjects (N = 80) were randomized to gabapentin (600 mg three times per day or 900 mg three times per day) or placebo. After a 2-week dose titration, the target dose was maintained for 9 weeks and then tapered over 1 week. Follow-up was for 12 weeks after the medication phase.
  
  
  RESULTS
  The study had high dropout rates with more than one half of participants in each arm discontinuing study. Gabapentin-treated participants exhibited lower abstinence rates than placebo-treated participants; however, this difference was not significant. Smoking reduction was observed across all treatment arms compared with baseline (p < .01) but did not differ across treatment groups.
  
  
  CONCLUSIONS
  Although not definitive, our findings suggest that gabapentin administered at these doses with this dosing regimen holds little promise for the treatment of tobacco dependence in a population of smokers seeking treatment.
authors.affiliation: Mayo Clinic College of Medicine, 200 1st Street Southwest, Rochester, MN 55905, USA.
authors.forename: Amit
authors.initials: A
authors.lastname: Sood
authors.forename: Jon O
authors.initials: JO
authors.lastname: Ebbert
authors.forename: Kirk D
authors.initials: KD
authors.lastname: Wyatt
authors.forename: Ivana T
authors.initials: IT
authors.lastname: Croghan
authors.forename: Darrell R
authors.initials: DR
authors.lastname: Schroeder
authors.forename: Richa
authors.initials: R
authors.lastname: Sood
authors.forename: J Taylor
authors.initials: JT
authors.lastname: Hays
mesh_terms: D000328:Adult; D000588:Amines / Q000008:administration & dosage / Q000627:therapeutic use*; D003509:Cyclohexanecarboxylic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D018691:Excitatory Amino Acid Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D000077206:Gabapentin; D006801:Humans; D008297:Male; D008875:Middle Aged; D016540:Smoking Cessation; D005680:gamma-Aminobutyric Acid / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000588:Amines; D003509:Cyclohexanecarboxylic Acids; D018691:Excitatory Amino Acid Antagonists; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin